Last reviewed · How we verify
HDM1002 placebo, oral, once daily, 52 weeks
HDM1002 placebo, oral, once daily, 52 weeks is a Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It is currently in Phase 3 development.
At a glance
| Generic name | HDM1002 placebo, oral, once daily, 52 weeks |
|---|---|
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDM1002 placebo, oral, once daily, 52 weeks CI brief — competitive landscape report
- HDM1002 placebo, oral, once daily, 52 weeks updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about HDM1002 placebo, oral, once daily, 52 weeks
What is HDM1002 placebo, oral, once daily, 52 weeks?
HDM1002 placebo, oral, once daily, 52 weeks is a Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd..
Who makes HDM1002 placebo, oral, once daily, 52 weeks?
HDM1002 placebo, oral, once daily, 52 weeks is developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (see full Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. pipeline at /company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd).
What development phase is HDM1002 placebo, oral, once daily, 52 weeks in?
HDM1002 placebo, oral, once daily, 52 weeks is in Phase 3.